A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator s choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma

15527MCLA-158-CL02-MWHCOpenA phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator s choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinomaMCLA-158-CL02NCT06496178IndustrialAdultTreatmentIIIGlobalLip, Oral Cavity and PharynxMerkhofer, CristinaMedStar Health and GUMC; Medstar Washington Hospital CenterThoracic/CNS/H&N/ThyroidOncology GroupMHRI Washington Cancer Institute2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>